

BÖLÜM 9

NÖRODEJENERATİF HASTALIKLARDA FARMASÖTİKLER VE KİŞİSEL BAKIM ÜRÜNLERİ: PATO FİZYOLOJİ, NÖROTOKSİSİTE VE KLİNİK PERSPEKTİF

Serap KURT ¹
Aylin KÖSELER ²

1. GİRİŞ

Nörodejeneratif hastalıklar, özellikle Alzheimer hastalığı (AD) ve Parkinson hastalığı (PD), günümüzde küresel ölçekte hızla artan en önemli sağlık sorunları arasında yer almaktadır. Dünya Sağlık Örgütü (WHO) verilerine göre, demansla yaşayan kişi sayısının 2050 yılına kadar üç kat artması beklenmektedir. Bu artış, yalnızca yaşlanma ile değil, aynı zamanda çevresel ve yaşam tarzına bağlı risk faktörleriyle de yakından ilişkilidir. Hastalıkların patogenezi, ilerleyici nöronal kayıp, oksidatif stres, protein agregasyonu, mitokondriyal disfonksiyon ve kronik nöro-inflamasyon gibi çok boyutlu biyolojik süreçlerle karakterize edilmektedir (1,2).

Son yıllarda, farmasötikler ve kişisel bakım ürünleri (pharmaceuticals and personal care products, PPCPs), yalnızca sağlık ve hijyen amacıyla kullanılan masum bileşenler olarak değil, aynı zamanda çevresel kirleticiler ve nörotoksik ajanlar olarak da ele alınmaya başlanmıştır. Farmasötik ve kişisel bakım ürünleri—antidepresanlar, nöroprotektif ajanlar, nonsteroid antiinflatuvarlar (NSAİİ’ler), antiepileptikler, antibiyotikler, UV filtreler, parabenler vb. —günümüzde yalnızca terapi amacıyla değil, aynı zamanda çevresel sapmalar yoluyla insan sağlığı üzerinde dolaylı ve potansiyel olarak nörolojik etki oluşturabilecek biyolojik ajanlar olarak da karşımıza çıkmaktadır. Bu grup bileşikler, kısaca **PPCP’ler (Pharma-**

¹ Arş. Gör. Dr., Manisa Celal Bayar Üniversitesi Tıp Fakültesi Tıbbi Genetik AD., serap.kurt@cbu.edu.tr, ORCID iD: 0000-0002-0186-7541

² Prof. Dr., Pamukkale Üniversitesi Tıp Fakültesi Temel Tıp Bilimleri Bölümü Biyofizik AD., akoseler@pau.edu.tr, ORCID iD: 0000-0003-4832-0436

KAYNAKLAR

1. Grandjean P, Landrigan PJ. Neurobehavioural effects of developmental toxicity. *Lancet Neurol.* 01 Mart 2014;13(3):330-8.
2. Lefèvre-Arbogast S, Chaker J, Mercier F, Barouki R, Coumoul X, Miller GW, vd. Assessing the contribution of the chemical exposome to neurodegenerative disease. *Nat Neurosci.* Mayıs 2024;27(5):812-21.
3. Barrera-Gómez J, Agier L, Portengen L, Chadeau-Hyam M, Giorgis-Allemand L, Siroux V, vd. A systematic comparison of statistical methods to detect interactions in exposome-health associations. *Environ Health.* 14 Temmuz 2017;16(1):74.
4. Richardson SD, Kimura SY. Emerging environmental contaminants: Challenges facing our next generation and potential engineering solutions. *Environ Technol Innov.* 01 Kasım 2017;8:40-56.
5. Ortúzar M, Esterhuizen M, Olicón-Hernández DR, González-López J, Aranda E. Pharmaceutical Pollution in Aquatic Environments: A Concise Review of Environmental Impacts and Bioremediation Systems. *Front Microbiol* [Internet]. 26 Nisan 2022 [a.yer 08 Eylül 2025];13. Erişim adresi: <https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.869332/full>
6. Pereira A, Silva L, Laranjeiro C, Lino C, Pena A. Selected Pharmaceuticals in Different Aquatic Compartments: Part I—Source, Fate and Occurrence. *Molecules.* 25 Şubat 2020;25(5):1026.
7. Szychowski PJ, Lech K, Sendra-Nadal E, Hernández F, Figiel A, Wojdyło A, vd. Kinetics, bio-compounds, antioxidant activity, and sensory attributes of quinces as affected by drying method. *Food Chem.* 30 Temmuz 2018;255:157-64.
8. Zheng W, Guo M. Soil–Plant Transfer of Pharmaceuticals and Personal Care Products. *Curr Pollut Rep.* Aralık 2021;7(4):510-23.
9. Eid A, Mhatre I, Richardson JR. Gene-environment interactions in Alzheimer's Disease: A potential path to precision medicine. *Pharmacol Ther.* 12 Mart 2019;199:173.
10. Gaspar L, Bartman S, Tobias-Wallingford H, Coppotelli G, Ross JM. Short-Term Exposure to Polystyrene Microplastics Alters Cognition, Immune, and Metabolic Markers in an APOE Genotype and Sex-Dependent Manner. *BioRxiv Prepr Serv Biol.* 08 Mayıs 2025;2025.05.02.651942.
11. Munoz N, Litchford M, Cox J, Nelson JL, Nie AM, Delmore B. Malnutrition and Pressure Injury Risk in Vulnerable Populations: Application of the 2019 International Clinical Practice Guideline. *Adv Skin Wound Care.* 01 Mart 2022;35(3):156-65.
12. aus der Beek T, Weber FA, Bergmann A, Hickmann S, Ebert I, Hein A, vd. Pharmaceuticals in the environment--Global occurrences and perspectives. *Environ Toxicol Chem.* Nisan 2016;35(4):823-35.
13. Zheng Y, Zhang L, Xiang Q, Li J, Yao Y, Sun H, vd. Human exposure characteristics of pharmaceutical and personal care product chemicals and associations with dietary habits. *Sci Total Environ.* 20 Ağustos 2024;939:173540.
14. Kümmerer K. Antibiotics in the aquatic environment--a review--part I. *Chemosphere.* Nisan 2009;75(4):417-34.
15. Kleywegt S, Pileggi V, Yang P, Hao C, Zhao X, Rocks C, vd. Pharmaceuticals, hormones and bisphenol A in untreated source and finished drinking water in Ontario, Canada--occurrence and treatment efficiency. *Sci Total Environ.* 15 Mart 2011;409(8):
16. Daughton CG, Ternes TA. Pharmaceuticals and personal care products in the environment: agents of subtle change? *Environ Health Perspect.* Aralık 1999;107 Suppl 6(Suppl 6):907-38.
17. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-Brain Barrier: From Physiology to Disease and Back. *Physiol Rev.* 01 Ocak 2019;99(1):21-78.
18. Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, vd. Ageing as a risk factor for neurodegenerative disease. *Nat Rev Neurol.* Ekim 2019;15(10):565-81.
19. Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. *Nat Neurosci.* Ekim 2018;21(10):1332-40.

20. Wang X, Wang W, Li L, Perry G, Lee H gon, Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. *Biochim Biophys Acta BBA - Mol Basis Dis.* 01 Ağustos 2014;1842(8):1240-7.
21. Cenini G, Voos W. Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update. *Front Pharmacol.* 2019;10:902.
22. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, vd. Neuroinflammation in Alzheimer's disease. *Lancet Neurol.* Nisan 2015;14(4):388-405.
23. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med.* Haziran 2016;8(6):595-608.
24. Brown-Leung JM, Cannon JR. Neurotransmission Targets of Per- and Polyfluoroalkyl Substance Neurotoxicity: Mechanisms and Potential Implications for Adverse Neurological Outcomes. *Chem Res Toxicol.* 15 Ağustos 2022;35(8):1312-33.
25. Valenti O, Gill KM, Grace AA. Different stressors produce excitation or inhibition of mesolimbic dopamine neuron activity: response alteration by stress pre-exposure. *Eur J Neurosci.* 2012;35(8):1312-21.
26. Azuma K, Uchiyama I, Uchiyama S, Kunugita N. Assessment of inhalation exposure to indoor air pollutants: Screening for health risks of multiple pollutants in Japanese dwellings. *Environ Res.* Şubat 2016;145:39-49.
27. Silman I, Sussman JL. Acetylcholinesterase: "classical" and "non-classical" functions and pharmacology. *Curr Opin Pharmacol.* Haziran 2005;5(3):293-302.
28. Arias-Cavieres A, More J, Vicente JM, Adasme T, Hidalgo J, Valdés JL, vd. Triclosan Impairs Hippocampal Synaptic Plasticity and Spatial Memory in Male Rats. *Front Mol Neurosci.* 2018;11:429.
29. Olaniyan LWB, Mkwetshana N, Okoh AI. Triclosan in water, implications for human and environmental health. *SpringerPlus.* 21 Eylül 2016;5(1):1639.
30. Adegoke EO, Rahman MS, Park YJ, Kim YJ, Pang MG. Endocrine-Disrupting Chemicals and Infectious Diseases: From Endocrine Disruption to Immunosuppression. *Int J Mol Sci.* 11 Nisan 2021;22(8):3939.
31. Newell ME, Aravindan A, Babbrah A, Halden RU. Epigenetic Biomarkers Driven by Environmental Toxins Associated with Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the United States: A Systematic Review. *Toxics.* Şubat 2025;13(2):114.
32. Binh VN, Dang N, Anh NTK, Ky LX, Thai PK. Antibiotics in the aquatic environment of Vietnam: Sources, concentrations, risk and control strategy. *Chemosphere.* 01 Nisan 2018;197:438-50.
33. Kim JH, Yan Q, Uppal K, Cui X, Ling C, Walker DI, vd. Metabolomics analysis of maternal serum exposed to high air pollution during pregnancy and risk of autism spectrum disorder in offspring. *Environ Res.* 01 Mayıs 2021;196:110823.
34. Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, vd. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. *JAMA.* 24 Nisan 2013;309(16):1696-703.
35. Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, vd. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. *Brain J Neurol.* 01 Temmuz 2018;141(7):1917-33.
36. Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, vd. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. *Mol Neurodegener.* 19 Ocak 2016;11:7.
37. Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, vd. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease. *JAMA Neurol.* 01 Mayıs 2017;74(5):525-32.
38. Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JRC, vd. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. *J Clin Invest.* Mayıs 2015;125(5):1979-86.81-8.